StockNews.AI
SYK
StockNews.AI
166 days

Inari Medical, now part of Stryker, launches Artix™ Thrombectomy System, designed to address a broad spectrum of arterial thrombus cases

1. Stryker launched Artix Thrombectomy System for arterial thromboembolism treatment. 2. Artix offers advanced control and effectiveness in removing arterial clots. 3. The system aims to reduce surgical interventions like open surgery or amputation. 4. First commercial use occurred on October 19, 2024, demonstrating immediate clinical applicability. 5. Artix is part of Stryker's strategy to innovate in medical technologies.

M&A
-0.69%Current Return
VS
+0.72%S&P 500
$381.93503/06 01:48 PM EDTEvent Start
$379.303/07 07:59 PM EDTLatest Updated
9m saved
Insight
Article

FAQ

Why Bullish?

The introduction of Artix positions SYK favorably in the expanding medical device market, particularly for vascular treatments, which can enhance revenue streams, similar to the impact observed post the announcements of other successful product launches. Historical examples include SYK's significant stock jumps post-acquisition of innovative medical technology firms, such as MAKO Surgical and Sage Products.

How important is it?

The launch of Artix is crucial for SYK's innovation narrative. It directly enhances Stryker's portfolio, addressing unmet medical needs which could lead to significant market share growth in vascular treatments.

Why Long Term?

Artix's integration will likely improve SYK's competitive positioning in the long term, akin to previous product launches that resulted in sustained revenue growth over several quarters.

Related Companies

MAKOSAGEBSX
, /PRNewswire/ -- Inari Medical, now part of Stryker (NYSE: SYK), a global leader in medical technologies, announced the launch of its Artix Thrombectomy System. Purpose-built for the distinct needs of the peripheral arterial system, Artix is a combined aspiration plus mechanical thrombectomy solution that delivers procedural control and versatility, and is designed to set a new standard for arterial thrombectomy. Artix™ Thrombectomy System An arterial blood clot in the leg is a life- and limb-threatening emergency requiring immediate treatment. However, existing therapies for arterial thromboembolism can lead to: Ineffective clot retrieval leading to additional procedures (open surgery or amputation1,2) Significant blood loss1 Adverse events such as arterial embolization and vessel trauma2,3 High rates of lytic use, which may result in complications1,2 The Artix System builds on the success of Inari's venous thrombectomy devices and is its inaugural entry into the arterial space. Inari offers a comprehensive toolkit approach to arterial thrombectomy with an innovative, over-the-wire system that provides physicians with the flexibility to aspirate and/or mechanically extract a clot.Jonathan Bowman, MD FACS, Chief of Vascular at Norwalk Hospital in Norwalk, CT, performed the first commercial case with Artix on October 19, 2024. "The Artix Thrombectomy System marks a significant advancement in peripheral arterial thromboembolism treatment," said Dr. Bowman. "With Artix, I finally have a solution that effectively addresses a wide range of clots while enabling me to maintain vessel access and retain control throughout the entire case. I expect Artix will take the place of open surgical repair in many of my arterial cases."Key distinctive features of the Artix system include: Dual mechanical thrombectomy and aspiration toolkit designed to remove acute to chronic clots in a single session via a streamlined procedure4 Aspiration-capable, 8 Fr. low profile, trackable, kink-resistant sheath in both 65cm and 90cm lengths expands treatment options by enabling more complex and distal interventions Innovative over-the-wire mechanical element designed to effectively collect and retrieve acute-to-chronic clot4 Covered nitinol mesh funnel provides temporary flow restriction during the procedure to minimize the risk of arterial clot migration5 "There is a real clinical need to address chronic thrombi and decrease the risk of clot migration. Artix will raise the bar of effective arterial thrombectomy," said Tom Tu, MD, Chief Medical Officer of Inari Medical. "We are excited to bring Inari's core competency in thrombectomy to the arterial space with the goal of improving outcomes."For more information, visit https://www.inarimedical.com/artix-system About StrykerStryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com.On February 19, 2025, Stryker acquired Inari Medical, a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases.Media contact:Sherri OaksonSenior Director, Communications MedSurg and Neurotechnology[email protected]  De Donato et al. The INDIAN Trial. Eur J Vasc Endovasc Surg. 2021; 61: 820-828. Heller et al. Percutaneous Mechanical Thrombectomy Using Rotarex Device in Acute Limb Ischemia in Infrainguinal Occlusions. BioMed Research International. 2017. Olinic et al. Acute Limb Ischemia: An Update on Diagnosis and Management. J Clin Med. 2019. Designed to remove acute to chronic arterial clots. According to benchtop testing compared to control. Internal data on file. Narula et al. JACC 2018;72:2153-63 According to benchtop testing compared to control. Internal data on file. NOTE: To attempt to minimize risk of arterial embolization of blood clots, use of a device that entraps clots may potentially be helpful, but this has not yet been demonstrated to be effective in the arterial system. Dr. Jonathan Bowman is a paid consultant of Inari Medical. All views and opinions expressed here by Dr. Jonathan Bowman are his own and do not represent those of Inari Medical.Indications for Use: The Artix thin-walled sheath is indicated for: (1) The non-surgical removal of emboli and thrombi from blood vessels. (2) Injection, infusion and/or aspiration of contrast media and other fluids into or from a blood vessel. (3) Use as a conduit for endovascular devices. (4) Use in facilitating the insertion and guidance of an intravascular catheter into a selected blood vessel. The funnel provides temporary vascular occlusion during these and other angiographic procedures. The Artix thin-walled sheath is intended for use in the peripheral vasculature. The Artix MT thrombectomy device is indicated for (1) the non-surgical removal of emboli and thrombi from a blood vessel; and (2) injection, infusion, and/or aspiration of contrast media and other fluids into or from a blood vessel. The Artix MT thrombectomy device is intended for use in the peripheral vasculature. The Artix AX aspiration catheter is indicated for (1) the non-surgical removal of emboli and thrombi from blood vessels; and (2) injection, infusion, and/or aspiration of contrast media and other fluids into or from a blood vessel. The Artix AX aspiration catheter is intended for use in the peripheral vasculature. The FlowSaver blood return system is used with Inari Medical catheters and sheaths for autologous blood transfusion.Review complete Instructions for Use, Indications for Use, Warnings, Precautions, Possible Adverse Effects and Contraindications prior to use of these products.SOURCE Stryker WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News